Cargando…

Combination of CLEC4M rs868875 G-Carriership and ABO O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients

The C-type lectin CLEC4M binds and internalizes factor VIII (FVIII). Common CLEC4M variants have been associated with FVIII pharmacokinetic (PK) profiles in hemophilia A (HA) patients. The two-compartment PK analysis of plasma-derived (pd-) and full length recombinant FVIII concentrates was conducte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lunghi, Barbara, Morfini, Massimo, Martinelli, Nicola, Linari, Silvia, Castaman, Giancarlo, Bernardi, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837058/ https://www.ncbi.nlm.nih.gov/pubmed/35160186 http://dx.doi.org/10.3390/jcm11030733

Ejemplares similares

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
por: Linari, Silvia, et al.
Publicado: (2020)

Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A
por: Castaman, Giancarlo, et al.
Publicado: (2016)

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1(+) Tregs
por: Becker-Gotot, Janine, et al.
Publicado: (2022)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)

Recombinant FVIII: the milestone of modern hemophilia treatment
por: Mannucci, Pier Mannuccio
Publicado: (2023)

Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
por: Nguyen, S., et al.
Publicado: (2019)

Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
por: Sung, Jin Jea, et al.
Publicado: (2019)

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
por: Mancuso, Maria Elisa, et al.
Publicado: (2014)

Managing Relevant Clinical Conditions of Hemophilia A/B Patients
por: Morfini, Massimo, et al.
Publicado: (2023)

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
por: Hemşinlioğlu, Cansu, et al.
Publicado: (2023)

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII
por: Hooimeijer, Louise H, et al.
Publicado: (2023)

Hemophilia A and B: molecular and clinical similarities and differences
por: Castaman, Giancarlo, et al.
Publicado: (2019)

Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders
por: Castaman, Giancarlo, et al.
Publicado: (2017)

Obstacles to Early Diagnosis and Treatment of Inherited von Willebrand Disease: Current Perspectives
por: Castaman, Giancarlo, et al.
Publicado: (2021)

Hemostatic Abnormalities in Gaucher Disease: Mechanisms and Clinical Implications
por: Linari, Silvia, et al.
Publicado: (2022)

Carriership of the rs113883650/rs2287120 haplotype of the SLC7A5 (LAT1) gene increases the risk of obesity in infants with phenylketonuria
por: Bik-Multanowski, Miroslaw, et al.
Publicado: (2020)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
por: Abolghasemi, Hassan, et al.
Publicado: (2018)

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022)

TNF-α/TNF-R System May Represent a Crucial Mediator of Proliferative Synovitis in Hemophilia A
por: Manetti, Mirko, et al.
Publicado: (2019)

Synthesis of FVIII in Hemophilia-A patients with the intron-22-inversion may modulate immunogenicity
por: Pandey, Gouri Shankar, et al.
Publicado: (2013)

FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
por: Hart, Daniel P.
Publicado: (2020)

The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A
por: Kim, Ju Young, et al.
Publicado: (2019)

The dataset from administration of single or combined immunomodulation agents to modulate anti-FVIII antibody responses in FVIII plasmid or protein primed hemophilia A mice
por: Liu, Chao Lien, et al.
Publicado: (2016)

The Arrival of Gene Therapy for Patients with Hemophilia A
por: Castaman, Giancarlo, et al.
Publicado: (2022)

Identification of FVIII gene mutations in patients with hemophilia A using new combinatorial sequencing by hybridization
por: Chetta, M., et al.
Publicado: (2008)

Development of an FVIII Inhibitor in a Mild Hemophilia Patient with a Phe595Cys Mutation
por: Yamanouchi, Jun, et al.
Publicado: (2018)

Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services
por: Oudat, Raida, et al.
Publicado: (2020)

Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A
por: Cai, Yuanhua, et al.
Publicado: (2020)

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
por: El-Akabawy, Nadia, et al.
Publicado: (2020)

The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A
por: Zimta, Alina-Andreea, et al.
Publicado: (2021)

Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience
por: Castaman, Giancarlo, et al.
Publicado: (2023)

Enteral Vancomycin to Eliminate MRSA Carriership of the Digestive Tract in Critically Ill Patients
por: Buitinck, Sophie H., et al.
Publicado: (2022)

Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A
por: Lytle, Allison M, et al.
Publicado: (2016)

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A
por: Trevisan, Brady, et al.
Publicado: (2021)

Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A
por: Elkouby, Liron, et al.
Publicado: (2021)

Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
por: Ai, Di, et al.
Publicado: (2022)

Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
por: Paul, Helmut, et al.
Publicado: (2022)

A graph-based machine learning framework identifies critical properties of FVIII that lead to hemophilia A
por: Ferreira, Marcos V., et al.
Publicado: (2023)

Hemophilia management: Huge impact of a tiny difference
por: Kloosterman, Fabienne, et al.
Publicado: (2020)

Significance of Gram's Stain in Rapid Intrapartum Screening for Maternal Carriership of Group B Streptococcus
por: Adriaanse, Albert H., et al.
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_gbu1v3vra96h3sdih6kuhd1cau